Biktarvy — bictegravir/emtricitabine/tenofovir-AF single-tablet ART

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-BICTEGRAVIR-EMTRICITABINE-TENOFOVIR-AF`

ID	`REG-HIV-BIKTARVY`
Type	Regimen
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NIH-AIDS-2024`

Notes

Biktarvy is a preferred first-line single-tablet ART regimen per DHHS / EACS / NIH AIDSinfo guidelines (2024). Combines bictegravir (integrase strand transfer inhibitor), emtricitabine (NRTI), tenofovir-AF (NRTI). High genetic barrier to resistance, well-tolerated, minimal drug-drug interactions vs. older PI-based regimens. Recommended for HIV-cancer-prevention pathway (per IND-CHRONIC-HIV-PREVENTION-ART). Drug-drug interaction screening mandatory before any cancer treatment is added.

Used By

Access Pathways

AP-ART-NSZU-HIV - ART regimens (Biktarvy and alternatives) via НСЗУ HIV programme

Contraindications

CI-BIKTARVY-RIFAMYCIN - CI-BIKTARVY-RIFAMYCIN
CI-TENOFOVIR-SEVERE-RENAL - CI-TENOFOVIR-SEVERE-RENAL

Disease

DIS-KAPOSI - Kaposi sarcoma

Indication

IND-CHRONIC-HIV-PREVENTION-ART - IND-CHRONIC-HIV-PREVENTION-ART
IND-KAPOSI-1L-AIDS-ART - IND-KAPOSI-1L-AIDS-ART
IND-KAPOSI-1L-VISCERAL-PLD - IND-KAPOSI-1L-VISCERAL-PLD